J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths

Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors